RayKnowChina Research Map
Shortlist0

RecruitingAmyotrophic lateral sclerosisPhase 4

Registered title, quoted from ClinicalTrials.gov

Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients

An open trial on amyotrophic lateral sclerosis, registered on ClinicalTrials.gov. Led by Peking University Third Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking University Third Hospital北京大学第三医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05923905, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. ALT or AST > 2 times ULN,creatinine clearance < 60 mL/min/1.73m2 (MDRD)

    Exclusion criterion 6

  3. Pregnant women and lactating women

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05923905, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • World Federation of Neurology modified El Ecorial criteria for diagnosis of patients with laboratory support probable, clinically probable, or definite sporadic and familial amyotrophic lateral sclerosis (ALS)
  • Age 18 to 80 years old
  • ALS duration no longer than 18 months(from day of onset)
  • Patient 's ALSFRS-R total scored ≥27,Each single item is scored at least 2(dyspnoea, orthopnea and respiratory insufficiency ≥3)
  • Forced vital capacity (FVC%) no less than 70% of predicted normal for gender, height and age
  • According to brain function AI analysis in accordance with depressive EEG characteristics
  • Women and men of childbearing potential should use medically acceptable contraception
  • Voluntarily participate, and sign an informed consent form

Exclusion Criteria:

  • Patients with dementia or severe neurological, psychiatric or systemic disease that is poorly controlled or may interfere with the conduct of the trial or the results of the trial
  • Pregnant women and lactating women
  • Suicide attempt or attempted suicide
  • Combined with other neurological diseases similar to ALS symptoms, or affecting the evaluation of drug efficacy, such as cervical spondylotic myelopathy, lumbar spondylosis, dementia, etc.
  • Patients with history of spinal surgery after ALS onset
  • ALT or AST > 2 times ULN,creatinine clearance < 60 mL/min/1.73m2 (MDRD)
  • Patients who are allergic to the investigational product
  • Having participated in other clinical studies within 3 months before randomization
  • Patients that the investigator considers unsuitable for participation in the study

Quoted from ClinicalTrials.gov, NCT05923905, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05923905, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05923905